Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Carlos Gallardo, Chairman of Almirall, will represent the company in a session scheduled at 9am Pacific Standard Timeon January 10th, 2023
Almirall’s executive team will host one-on-one investor and business development meetings in
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients’ needs.
The company, founded in 1943 and headquartered in
For more information, please visit almirall.com
This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005535/en/
Media contact Almirall:
Phone: (+34) 600 430 581
Investors’ Relations contact
Phone: (+34) 93 291 3087
Corporate Communications contact:
Phone: (+34) 659 614 173